In this regard, the exploration of tau oligomer‐specific monoclonal antibodies to remove pathogenic soluble aggregated tau in mice models of tauopathies showed the ability to ameliorate microvasculature dysfunction.7 The gene discussed is MAPT; the disease is tauopathy.